## STATUS OF THE CLAIMS

Claims 1 to 10 (Currently cancelled)

- 11. A method for screening agents which inhibit an angiogenic response comprising
  - a) contacting:
    - i) an inactive pro form or convertase-activated form of an integrin  $\alpha$  subunit involved in angiogenesis,
    - ii) an agent to be tested for the ability to inhibit angiogenesis, and
    - iii) metalloprotease MT1-MMP,

under conditions promoting an increase in activation of the integrin  $\alpha$  subunit in the absence of said agent, and

- b) correlating inhibition of said increase in integrin  $\alpha$  subunit activation with the ability of the agent to inhibit angiogenesis.
- 12. The method of claim 11 wherein the correlating step is accomplished by observing a difference in migration of the activated form versus the inactive form of the alpha subunit in electrophoresis or chromatography.
- 13. The method of claim 11 wherein the MT1-MMP and pro form of the integrin  $\alpha$  subunit are recombinantly expressed within the same cell.
- 14. The method of claim 11 in which said contacting step is performed within a cell.
- 15. The method of claim 11 in which the activation of said alpha subunit is accomplished by cleavage of the pro form of said alpha subunit.
- 16. The method of claim 1 wherein the activation of said alpha subunit is accompanied by a change in glycolsylation of the pro form of said alpha subunit.

Docket No. 17430CON(AP) Page 4

17. The method of any one of the foregoing claims in which the alpha subunit comprises the  $\alpha_V$  subunit.